Valuation: Verastem, Inc.

Market Cap 510M 443M 412M 379M 715M 48.65B 726M 4.86B 1.91B 24.22B 1.91B 1.87B 81.22B P/E 2026 *
-3.66x
P/E 2027 * -5.17x
Enterprise Value 345M 300M 279M 256M 484M 32.9B 491M 3.29B 1.29B 16.38B 1.29B 1.27B 54.93B EV / Sales 2026 *
3.38x
EV / Sales 2027 * 1.68x
Free-Float
99.07%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Verastem, Inc.

1 day-4.92%
1 week-4.13%
1 month+51.83%
3 months+6.23%
6 months-4.92%
Current year-24.87%
1 week 5.54
Extreme 5.54
6.46
1 month 4.07
Extreme 4.07
6.46
Current year 3.43
Extreme 3.43
8.88
1 year 3.43
Extreme 3.43
11.24
3 years 2.1
Extreme 2.1
14.22
5 years 2.1
Extreme 2.1
42.96
10 years 2.1
Extreme 2.1
124.2
Manager TitleAgeSince
Chief Executive Officer 65 01/08/2023
Director of Finance/CFO 39 31/10/2022
Chief Tech/Sci/R&D Officer - 18/04/2024
Director TitleAgeSince
Chairman 62 -
Director/Board Member 65 01/08/2023
Director/Board Member 69 03/05/2017
Date Insider Type Main position Quantity % Market Cap.
21/5/26 Free

Chairman

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
21/5/26 Free

Director

36,000 0.0410%
Change 5-day change 1-year change 3-year change Capi.($)
-4.92%-4.13%-6.00%-47.56% 510M
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average -0.61%-3.83%+30.43%+136.86% 23.44B
Weighted average by Cap. +0.22%-2.96%+28.60%+119.62%

Financials

2026 *2027 *
Net sales 102M 88.56M 82.43M 75.68M 143M 9.72B 145M 972M 381M 4.84B 383M 374M 16.23B 178M 155M 144M 132M 250M 17.03B 254M 1.7B 668M 8.48B 670M 655M 28.42B
Net income -166M -144M -134M -123M -232M -15.8B -236M -1.58B -620M -7.87B -622M -608M -26.38B -142M -123M -115M -106M -199M -13.56B -202M -1.35B -532M -6.75B -534M -522M -22.64B
Net Debt -165M -143M -134M -123M -231M -15.75B -235M -1.57B -618M -7.84B -620M -606M -26.29B -210M -182M -170M -156M -294M -20.01B -299M -2B -785M -9.96B -787M -770M -33.4B
Logo Verastem, Inc.
Verastem, Inc. is a late-stage development biopharmaceutical company, which focuses on the development and commercialization of new medicines to improve the lives of patients diagnosed with ras sarcoma (RAS)/ mitogen-activated pathway kinase (MAPK) pathway-driven cancers. Its product candidates include avutometinib and defactinib. Avutometinib is an oral RAF/MEK clamp that inhibits MEK1/2 kinase activities and induces inactive complexes of MEK with A-Raf proto-oncogene, potentially serine/threonine kinase (ARAF), B-Raf proto-oncogene serine/threonine kinase (BRAF) and C-raf proto-oncogene serine/threonine kinase, creating antitumor response through maximal RAS/MAPK pathway inhibition. Defactinib is an oral, selective inhibitor of FAK and proline-rich tyrosine kinase (PYK2), the two members of the focal adhesion kinase family of non-receptor protein tyrosine kinases. FAK and PYK2 integrate signals from integrin and growth factor receptors to regulate cell proliferation.
Employees
102
Date Price Change Volume
31/07/26 US$5.800 -4.92% 1,857,262
30/07/26 US$6.100 +1.50% 1,451,955
29/07/26 US$6.010 -3.53% 2,249,888
28/07/26 US$6.230 +2.47% 1,275,019
27/07/26 US$6.080 +0.50% 2,244,215
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
5.800USD
Average target price
15.00USD
Spread / Average Target
+158.62%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VSTM Stock